CVI Holdings’s Definium Therapeutics DFTX Stock Holding History

CVI Holdings’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-652,374	Closed	-$2.28M	–	637
2022 Q3	$2.28M	Buy	+652,374	New	+$6.26M	0.18%	201

Other funds holding DFTX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

CVI Holdings's DFTX Position: Q4 2022 in Review

CVI Holdings sold out of Definium Therapeutics (DFTX) in Q4 2022, closing a stake of 652,374 shares — an estimated $2.28M sold.

CVI Holdings first reported a position in DFTX in Q3 2022 and held it in 1 quarter. The position peaked at $2.28M in Q3 2022. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2022.

CVI Holdings reported no remaining Definium Therapeutics position as of Q4 2022 after selling out during the quarter.
CVI Holdings sold 652,374 Definium Therapeutics shares in Q4 2022, an estimated $2.28M.
CVI Holdings first reported a position in Definium Therapeutics in Q3 2022 and held it in 1 quarter.
CVI Holdings's Definium Therapeutics position peaked at $2.28M in Q3 2022.
104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2022.

Based on CVI Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.